A novel KMT2A-USO1 fusion gene-induced de novo secondary acute myeloid leukaemia in a patient initially diagnosed with acute promyelocytic leukaemia

Br J Haematol. 2021 Jan;192(1):e32-e36. doi: 10.1111/bjh.17183. Epub 2020 Nov 20.

Authors

Wen Jin¹, Li Chen¹, Yabin Liu¹, Qiusheng Chen¹, Ming Zhao¹, Yun Tan¹, Wei Zhang¹, Huan Song¹, Xiangqin Weng¹, Jianqing Mi¹, Saijuan Chen^{1

2}, Zhu Chen^{1

2}, Junmin Li¹, Kankan Wang^{1

2}

Affiliations

¹ Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
² CNRS-LIA Hematology and Cancer, Sino-French Research Center for Life Sciences and Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

PMID: 33216970
DOI: 10.1111/bjh.17183

No abstract available

Keywords: KMT2A-USO1; acute promyelocytic leukemia; clonal evolution; pre-leukemic event; secondary acute myeloid leukemia.

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Golgi Matrix Proteins / genetics*
Histone-Lysine N-Methyltransferase / genetics*
Humans
Leukemia, Myeloid, Acute / diagnosis
Leukemia, Myeloid, Acute / genetics*
Leukemia, Promyelocytic, Acute / diagnosis
Leukemia, Promyelocytic, Acute / genetics
Male
Middle Aged
Myeloid-Lymphoid Leukemia Protein / genetics*
Oncogene Proteins, Fusion / genetics*
Vesicular Transport Proteins / genetics*

Substances

Golgi Matrix Proteins
KMT2A protein, human
Oncogene Proteins, Fusion
Vesicular Transport Proteins
Myeloid-Lymphoid Leukemia Protein
vesicular transport factor p115
Histone-Lysine N-Methyltransferase

Grants and funding